(Albany, US), September 10, 2026- DelveInsight’s “Chronic Myeloid Leukaemia Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Chronic Myeloid Leukaemia pipeline landscape. It covers the Chronic Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Chronic Myeloid Leukemia Treatment Landscape @ https://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-pipeline-insight
Key Takeaways from the Chronic Myeloid Leukemia Pipeline Report
Discover groundbreaking developments in Chronic Myeloid Leukemia Therapies! @ Chronic Myeloid Leukemia Ongoing Clinical Trials Assessment
Chronic Myeloid Leukemia Overview
Chronic myeloid leukemia is also known as chronic myelogenous leukemia. It’s a type of cancer that starts in certain blood-forming cells of the bone marrow. In CML, a genetic change takes place in an early (immature) version of myeloid cells — the cells that make red blood cells, platelets, and most types of white blood cells (except lymphocytes). This change forms an abnormal gene called BCR-ABL, which turns the cell into a CML cell. The leukemia cells grow and divide, building up in the bone marrow and spilling over into the blood. In time, the cells can also settle in other parts of the body, including the spleen. CML is a fairly slow-growing leukemia, but it can change into a fast-growing acute leukemia that’s hard to treat. CML does not usually cause any symptoms in its early stages and may only be picked up during tests carried out for another reason. As the condition develops, symptoms can include tiredness, weight loss, night sweats, tenderness and swelling in the left side of your tummy, feeling full after small meals, pale skin and shortness of breath and a high temperature.
Chronic Myeloid Leukemia Emerging Drugs Profile
RS‑5614 is an investigational therapy being developed by Renascience for the treatment of CML. RS5614 has passed all non-clinical safety tests required for clinical trials and manufacturing and sales as a drug. In addition, RS5614 has been administered to nearly 400 subjects (healthy people, chronic myeloid leukemia, novel coronavirus lung injury, malignant melanoma, lung cancer, systemic sclerosis, etc.), and long-term administration for one year was also performed for chronic myeloid leukemia, but no problematic side effects due to RS5614 have been reported, and it is considered to be a highly safe drug. In the past, many pharmaceutical companies and bio start-ups, both in Japan and overseas, have been working on developing small molecule PAI-1 inhibitors, and some of the drugs have been reported to be effective in animal models of mice and rats. However, all of these were discontinued at an early stage of development, and our drug is the oral PAI-1 inhibitor currently in the human clinical stage. Currently the drug is in Phase III stage of development for the treatment of CML.
ABL001 is an investigational targeted therapy developed by Novartis Pharmaceuticals for the treatment of Chronic Myeloid Leukemia and other cancers. It is a small‑molecule allosteric inhibitor that specifically binds to the myristoyl pocket of the BCR‑ABL1 fusion protein, a key driver of CML. By targeting the BCR‑ABL1 oncoprotein through a distinct mechanism from traditional tyrosine kinase inhibitors, ABL001 aims to overcome resistance and improve disease control. The drug is being evaluated in clinical studies to assess its safety, tolerability, and efficacy in patients with CML, including those with resistant or refractory disease. Currently the drug is in Phase II stage of development for the treatment of CML.
ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with Chronic Myeloid Leukemia. ELVN-001 targets the ATP-binding site of the ABL1 kinase domain and binds to a unique P-loop “folded-in” active conformation of ABL1, creating a narrow selectivity tunnel against the broader kinome. ELVN-001 was also designed to have activity against the T315I mutation, the most common BCR-ABL mutation, which confers resistance to nearly all approved tyrosine kinase inhibitors (TKIs), as well as activity against mutations known to confer resistance to allosteric BCR-ABL inhibitors. As per the company pipeline, the drug is in Phase I stage of its clinical trial for the treatment of Chronic Myeloid Leukemia.
MGD024 is an investigational bispecific DART® molecule being developed by MacroGenics for the treatment of Chronic Myeloid Leukemia and other hematologic malignancies. It simultaneously engages CD123 on leukemic cells and CD3 on T‑cells, directing cytotoxic T‑cell activity against malignant cells. By harnessing the immune system, MGD024 aims to eliminate leukemic cells more effectively than conventional therapies. The drug is currently in early‑stage clinical development, with studies evaluating its safety, tolerability, and anti‑leukemic activity in patients with CML and related disorders.
The Chronic Myeloid Leukemia Pipeline Report Provides Insights into
Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Chronic Myeloid Leukemia Unmet Needs
Chronic Myeloid Leukemia Companies
Renascience, Novartis Pharmaceuticals, AOP Orphan Pharmaceuticals GmbH, ImmunoForge, Enliven Therapeutics, MacroGenics and others.
Chronic Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Chronic Myeloid Leukemia Products have been categorized under various Molecule types such as
See the latest progress in drug development and clinical research @ Chronic Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives
Scope of the Chronic Myeloid Leukemia Pipeline Report
Access the Full Chronic Myeloid Leukemia Pipeline Analysis Today! @ Chronic Myeloid Leukemia Drugs and Companies
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-pipeline-insight
